摩根士丹利下調對石藥(01093.HK)今明兩年盈利預測3%至4%，反映成藥銷售增加被維他命C及咖啡因銷售下降抵銷，以及基於更低的銷售與行政開支比率導致的更好毛利率與淨利潤率。
該行上調往後年度的盈利預測2%至5%，以反映新藥可能更快推出，目標價由11元上調至12元，維持「增持」評級。
《大行》大摩升石藥集團(01093.HK)目標價至12元 評級「增持」
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.